KLP Kapitalforvaltning AS Purchases Shares of 25,700 Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

KLP Kapitalforvaltning AS purchased a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 25,700 shares of the specialty pharmaceutical company's stock, valued at approximately $736,000. KLP Kapitalforvaltning AS owned approximately 0.08% of Collegium Pharmaceutical at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Hillsdale Investment Management Inc. increased its position in shares of Collegium Pharmaceutical by 1.0% during the fourth quarter. Hillsdale Investment Management Inc. now owns 116,200 shares of the specialty pharmaceutical company's stock worth $3,329,000 after acquiring an additional 1,100 shares in the last quarter. Summit Global Investments purchased a new stake in Collegium Pharmaceutical in the 4th quarter valued at $232,000. Teacher Retirement System of Texas grew its stake in shares of Collegium Pharmaceutical by 16.6% in the 4th quarter. Teacher Retirement System of Texas now owns 9,568 shares of the specialty pharmaceutical company's stock worth $274,000 after acquiring an additional 1,363 shares in the last quarter. Intech Investment Management LLC lifted its position in shares of Collegium Pharmaceutical by 593.7% during the fourth quarter. Intech Investment Management LLC now owns 67,132 shares of the specialty pharmaceutical company's stock valued at $1,923,000 after purchasing an additional 57,455 shares in the last quarter. Finally, Tejara Capital Ltd purchased a new stake in Collegium Pharmaceutical in the 4th quarter valued at about $825,000.

Remove Ads

Insider Buying and Selling

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 2,255 shares of the firm's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $30.00, for a total value of $67,650.00. Following the sale, the executive vice president now owns 124,421 shares of the company's stock, valued at $3,732,630. This trade represents a 1.78 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the business's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the transaction, the executive vice president now directly owns 154,204 shares of the company's stock, valued at $4,330,048.32. The trade was a 20.60 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 109,193 shares of company stock valued at $3,243,594. Company insiders own 3.98% of the company's stock.

Wall Street Analysts Forecast Growth

COLL has been the subject of a number of research analyst reports. Piper Sandler decreased their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a research report on Tuesday, February 4th. HC Wainwright restated a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Monday, March 24th. Finally, Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 target price on the stock in a research note on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $43.60.

Collegium Pharmaceutical Stock Performance

NASDAQ COLL traded down $0.88 during trading on Friday, hitting $28.14. 384,608 shares of the company's stock traded hands, compared to its average volume of 438,072. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The stock has a market capitalization of $904.19 million, a price-to-earnings ratio of 12.13 and a beta of 0.76. Collegium Pharmaceutical, Inc. has a 12-month low of $27.28 and a 12-month high of $42.29. The business has a 50 day moving average of $30.02 and a 200-day moving average of $32.11.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The company had revenue of $181.95 million during the quarter, compared to the consensus estimate of $179.68 million. As a group, equities research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.